These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 35322226

  • 1. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M.
    Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD, Othee H, Chan KA, Man DC, Belliveau PP, Towle J.
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
    Maurer MS.
    Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF, Hahn K.
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 11. Treating hereditary transthyretin amyloidosis: Present & future challenges.
    Echaniz-Laguna A, Cauquil C, Labeyrie C, Adams D.
    Rev Neurol (Paris); 2023 Sep; 179(1-2):30-34. PubMed ID: 36150937
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D, Di Stefano V, Brighina F, Galassi AR, Novo G.
    Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
    [Abstract] [Full Text] [Related]

  • 16. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
    Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D.
    N Engl J Med; 2021 Aug 05; 385(6):493-502. PubMed ID: 34215024
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.